Skip to main content

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology

Lymphoma
Rituximab Maintenance Extends Remission in Follicular Lymphoma, but Overall Survival Unaffected
Caroline Helwick
Read More
Lymphoma
Surveillance Scanning in Transformed Indolent Lymphoma of Limited Clinical Benefit
Wayne Kuznar
Read More
Lymphoma
PI3K Inhibitors Main Focus of Drug Pipeline for Lymphoma
Caroline Helwick
Read More
Promise of Genomic Sequencing for Clinical Decision-Making in Hematopoietic Cancers
Wayne Kuznar
Read More
Multiple Myeloma, Oncology
Myeloma Drug Arsenal Expanding to New Classes
Caroline Helwick
Read More
Multiple Myeloma, Oncology
Lenalidomide Maintenance in Transplant-Eligible Myeloma Population Still Debated
Caroline Helwick
Read More
Multiple Myeloma, Oncology
FIRST Trial Shows Value for Continued Use of Lenalidomide in Transplant-Ineligible Patients with Newly Diagnosed Myeloma
Caroline Helwick
Read More
Leukemia, Oncology
Nilotinib Sustains Deeper Molecular Response versus Imatinib in Patients with Ph+ CML
Wayne Kuznar
Read More
Novel CAR-T Therapy Topped the News at ASH 2013
Caroline Helwick
Read More
Leukemia, Oncology
Novel Anti-CD20 Antibodies Show Promising Results in Unfit Patients with Chronic Lymphocytic Leukemia
Wayne Kuznar
Read More
Page 2 of 4
Results 11 - 20 of 32